# A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

> **NCT02052375** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Pharmacokinetics of ASP2408

## Interventions

- **DRUG:** ASP2408
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02052375
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052375, "A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02052375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*